Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)

Stock Information for Inovio Pharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Inovio Pharmaceuticals Inc.

INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Inseego Corp. to Report First Quarter 2024 Financial Results on May 9, 2024
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Inseego reports Fourth Quarter and Full Year 2023 Financial Results and announces CEO transition
INOVIO to Report Fourth Quarter and Year-End 2023 Financial Results on March 6, 2024
INOVIO to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.